Orchid Pharma partners with Cipla to launch antibiotic Cefepime-Enmetazobactam in India on Thursday, June 28. The company presents its board meeting and press release on June 28. The company informs the exchange on Thursday. In a landmark collaboration, Orchid Pharma has partnered with Cipla Limited to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India
Orchid Pharma Limited is the only Indian pharmaceutical company to have ever invented a New Chemical Entity (NCE), today announced the launch of its new drug – Cefepime-Enmwtazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications.
About Orchid Pharma Limited
Established in 1992 as an export-oriented unit (EOU), Orchid Pharma Ltd. is a vertically integrated Company spanning the entire pharmaceutical value chain with established credentials in research, manufacturing and marketing.
About Cipla
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics and deepening portfolio in our home markets of India, Sauth Africa, North America and key regulated and emerging markets.